Both (IVM/HCQ) are not patented so there is no reason to depend or trust on multinational pharmaceutical companies.

You can access interactive meta analysis of 310 studies for HCQ[1] and 78 studies for ivermectin[2] below, it gets updated when new studies published. They also keep track of other treatments (in total 480[3]). But unfortunately only some of those treatments get media coverage like cannabidiol[4] even when they are neither the best performers nor best studied.

[1]: https://hcqmeta.com/ [2]: https://ivmmeta.com/ [3]: https://c19early.com/ [4]: https://c19early.com/cbdmeta.html

Very little profit, that's for sure.

The benefit of repurposing drugs is precisely that we have decades of safety profile data. That's why those are particularly interesting against emerging diseases, especially for low income countries.

Obviously that's an issue for big pharma since they're not competitive when it comes to pure manufacturing of cheap drugs.